IL148366A0 - Selective antagonists of a2b adenosine receptors - Google Patents
Selective antagonists of a2b adenosine receptorsInfo
- Publication number
- IL148366A0 IL148366A0 IL14836600A IL14836600A IL148366A0 IL 148366 A0 IL148366 A0 IL 148366A0 IL 14836600 A IL14836600 A IL 14836600A IL 14836600 A IL14836600 A IL 14836600A IL 148366 A0 IL148366 A0 IL 148366A0
- Authority
- IL
- Israel
- Prior art keywords
- adenosine receptors
- selective antagonists
- antagonists
- selective
- adenosine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15164999P | 1999-08-31 | 1999-08-31 | |
PCT/US2000/040751 WO2001016134A1 (en) | 1999-08-31 | 2000-08-28 | Selective antagonists of a2b adenosine receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL148366A0 true IL148366A0 (en) | 2002-09-12 |
Family
ID=22539669
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14836600A IL148366A0 (en) | 1999-08-31 | 2000-08-28 | Selective antagonists of a2b adenosine receptors |
IL148366A IL148366A (en) | 1999-08-31 | 2002-02-25 | History of 3 - Isobutylxanthine - 8 - amino and their use as adenosine A2B receptor antagonists |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL148366A IL148366A (en) | 1999-08-31 | 2002-02-25 | History of 3 - Isobutylxanthine - 8 - amino and their use as adenosine A2B receptor antagonists |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1208100B1 (ja) |
JP (1) | JP3914434B2 (ja) |
KR (1) | KR100502757B1 (ja) |
CN (1) | CN1178940C (ja) |
AR (1) | AR029178A1 (ja) |
AT (1) | ATE236160T1 (ja) |
AU (1) | AU760071B2 (ja) |
BR (1) | BR0013673A (ja) |
CA (1) | CA2383351C (ja) |
DE (1) | DE60001969T2 (ja) |
DK (1) | DK1208100T3 (ja) |
ES (1) | ES2190422T3 (ja) |
HK (1) | HK1049835B (ja) |
IL (2) | IL148366A0 (ja) |
MX (1) | MXPA02002262A (ja) |
NO (1) | NO328489B1 (ja) |
NZ (1) | NZ517546A (ja) |
PT (1) | PT1208100E (ja) |
TR (1) | TR200201132T2 (ja) |
TW (1) | TWI262921B (ja) |
WO (1) | WO2001016134A1 (ja) |
ZA (1) | ZA200201650B (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
AU2001238665A1 (en) | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
ES2247356T3 (es) | 2001-06-29 | 2006-03-01 | Cv Therapeutics, Inc. | Derivados de purina com antagonistas del receptor a2b de adenosina. |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US7022710B2 (en) | 2003-07-22 | 2006-04-04 | Cv Therapeutics, Inc. | A1 adenosine receptor antagonists |
WO2005053695A1 (ja) * | 2003-12-04 | 2005-06-16 | Eisai Co., Ltd. | 多発性硬化症予防剤または治療剤 |
EP1781657B1 (en) * | 2004-02-14 | 2013-03-27 | GlaxoSmithKline Intellectual Property Development Limited | Medicaments with hm74a receptor activity |
WO2006044610A1 (en) * | 2004-10-15 | 2006-04-27 | Cv Therapeutics, Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
CA2583185A1 (en) | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
EP2581381A3 (en) | 2006-02-03 | 2013-10-30 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
EP3389664A4 (en) * | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7810946L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
ES2148170T3 (es) * | 1990-12-21 | 2000-10-16 | Beecham Group Plc | Derivados de xantina. |
GB9210839D0 (en) * | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-08-28 JP JP2001519700A patent/JP3914434B2/ja not_active Expired - Fee Related
- 2000-08-28 ES ES00971055T patent/ES2190422T3/es not_active Expired - Lifetime
- 2000-08-28 AU AU80348/00A patent/AU760071B2/en not_active Ceased
- 2000-08-28 BR BR0013673-5A patent/BR0013673A/pt not_active Application Discontinuation
- 2000-08-28 CA CA002383351A patent/CA2383351C/en not_active Expired - Fee Related
- 2000-08-28 PT PT00971055T patent/PT1208100E/pt unknown
- 2000-08-28 AT AT00971055T patent/ATE236160T1/de not_active IP Right Cessation
- 2000-08-28 IL IL14836600A patent/IL148366A0/xx active IP Right Grant
- 2000-08-28 DK DK00971055T patent/DK1208100T3/da active
- 2000-08-28 MX MXPA02002262A patent/MXPA02002262A/es active IP Right Grant
- 2000-08-28 EP EP00971055A patent/EP1208100B1/en not_active Expired - Lifetime
- 2000-08-28 DE DE60001969T patent/DE60001969T2/de not_active Expired - Lifetime
- 2000-08-28 WO PCT/US2000/040751 patent/WO2001016134A1/en not_active Application Discontinuation
- 2000-08-28 CN CNB00813717XA patent/CN1178940C/zh not_active Expired - Fee Related
- 2000-08-28 KR KR10-2002-7002718A patent/KR100502757B1/ko not_active IP Right Cessation
- 2000-08-28 NZ NZ517546A patent/NZ517546A/en unknown
- 2000-08-28 TR TR2002/01132T patent/TR200201132T2/xx unknown
- 2000-08-30 AR ARP000104523A patent/AR029178A1/es active IP Right Grant
- 2000-09-21 TW TW089117772A patent/TWI262921B/zh not_active IP Right Cessation
-
2002
- 2002-02-25 IL IL148366A patent/IL148366A/en not_active IP Right Cessation
- 2002-02-27 ZA ZA200201650A patent/ZA200201650B/en unknown
- 2002-02-27 NO NO20020979A patent/NO328489B1/no not_active IP Right Cessation
-
2003
- 2003-03-14 HK HK03101920.0A patent/HK1049835B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP3914434B2 (ja) | 2007-05-16 |
CN1178940C (zh) | 2004-12-08 |
DE60001969T2 (de) | 2004-02-05 |
CN1377352A (zh) | 2002-10-30 |
IL148366A (en) | 2006-12-10 |
CA2383351C (en) | 2005-11-01 |
TR200201132T2 (tr) | 2002-08-21 |
MXPA02002262A (es) | 2002-09-30 |
NZ517546A (en) | 2003-10-31 |
ATE236160T1 (de) | 2003-04-15 |
NO20020979L (no) | 2002-04-26 |
AU8034800A (en) | 2001-03-26 |
JP2003508398A (ja) | 2003-03-04 |
DE60001969D1 (de) | 2003-05-08 |
HK1049835B (zh) | 2005-04-08 |
DK1208100T3 (da) | 2003-06-30 |
NO20020979D0 (no) | 2002-02-27 |
EP1208100B1 (en) | 2003-04-02 |
KR20020041419A (ko) | 2002-06-01 |
CA2383351A1 (en) | 2001-03-08 |
BR0013673A (pt) | 2002-05-28 |
AR029178A1 (es) | 2003-06-18 |
PT1208100E (pt) | 2003-07-31 |
ZA200201650B (en) | 2003-05-28 |
HK1049835A1 (en) | 2003-05-30 |
EP1208100A1 (en) | 2002-05-29 |
WO2001016134A1 (en) | 2001-03-08 |
AU760071B2 (en) | 2003-05-08 |
KR100502757B1 (ko) | 2005-07-22 |
TWI262921B (en) | 2006-10-01 |
ES2190422T3 (es) | 2003-08-01 |
NO328489B1 (no) | 2010-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2875999A (en) | Antagonists of a2b human adenosine receptors | |
HUP0401925A3 (en) | A2b adenosine receptor antagonists | |
AU5316000A (en) | Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors | |
AU6808901A (en) | Adenosine a2a receptor antagonists | |
IL148366A0 (en) | Selective antagonists of a2b adenosine receptors | |
HK1063780A1 (en) | Adenosine a2a receptor antagonists | |
IL175759A0 (en) | A2b adenosine receptor antagonists | |
MXPA03004439A (es) | Aminotiazoles y su uso como antagonistas del receptor de adenosina. | |
IS5706A (is) | Adenosín A3 viðtakastillar | |
IL147198A0 (en) | N-pyrazole a2a receptor agonists | |
IL147195A0 (en) | C-pyrazole a2a receptor agonists | |
IL158214A0 (en) | 8-heteroaryl xanthine adenosine a2b receptor antagonists | |
HUP0202202A3 (en) | Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof | |
HUP0401437A3 (en) | Adenosine a3 receptor agonists | |
HUP0201184A3 (en) | Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction | |
HK1064097A1 (en) | Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists | |
PL356990A1 (en) | Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists | |
HUP0203371A3 (en) | Adenosine receptor antagonists and methods of making and using the same | |
AU3958902A (en) | Crf receptor antagonists and methods relating thereto | |
PL370565A1 (en) | 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists | |
AU3167402A (en) | Aminotriazolopyridiine derivatives as adenosine receptor ligands | |
HK1047750A1 (zh) | 趨化因子受體拮抗劑 | |
AU2574801A (en) | Selective iGLUR5 receptor antagonists | |
IL142362A0 (en) | Ureidopiperidine derivatives as selective human nk3 receptor antagonists | |
EP1102587A4 (en) | vitronectin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted |